Marklund, M., Mattingly, T. J., Sahoo, S. K., Kaur, P., Moran, A. E., Appel, L. J., & Matsushita, K. (2025). Effects of medication procurement reforms and extended prescription duration on medication coverage for hypertension in India’s public health system: a modelling study. BMJ Public Health, 3(1), e001044. https://doi.org/10.1136/bmjph-2024-001044

Alam, M., Shi, V. J., Maisel-Campbell, A., Cressey, B. D., Nadir, U., Koza, E., Haq, M., Ahmed, A., Ma, M. S., Weil, A., Cahn, B. A., Lee, A. Y., Shapiro, S., & Poon, E. (2024). US FDA Advisory Panel Members’ Assessment of Premarket Approval Process and Suggestions for Improvement. JAMA Network Open, 7(10), e2436066. https://doi.org/10.1001/jamanetworkopen.2024.36066

Kwan, M. L., Pimentel, N., Izano, M., Iribarren, C., Rana, J. S., Nguyen-Huynh, M., Cheng, R., Laurent, C. A., Lee, V. S., Roh, J. M., Rillamas-Sun, E., Hershman, D. L., Kushi, L. H., Greenlee, H., & Neugebauer, R. (2024). Adherence to cardiovascular medications and risk of cardiovascular disease in breast cancer patients: A causal inference approach in the Pathways Heart Study. PLOS ONE, 19(9), e0310531. https://doi.org/10.1371/journal.pone.0310531

Boursiquot, B. C., Jackson, L. R., & Essien, U. R. (2024). Advancing Pharmacoequity in Atrial Fibrillation—The Case for Direct Oral Anticoagulants. JAMA Network Open, 7(5), e249403. https://doi.org/10.1001/jamanetworkopen.2024.9403

Gong, Z., Umoru, G., Monge, J., Shah, N., Mohyuddin, G. R., Radhakrishnan, S., Chakraborty, R., Schinke, C., D’Souza, A., & Mohan, M. (2023). Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study. Blood, 142(Supplement 1), 358–358. https://doi.org/10.1182/blood-2023-182695

Mullangi, S., Chen, X., Pham, T., Liu, Y., Gordon, A. S., Debono, D., Fisch, M. J., Gönen, M., & Hershman, D. L. (2023). Association of Patient, Physician, and Practice-Level Factors with Uptake of Payer-Led Oncology Clinical Pathways. JAMA Network Open, 6(5), e2312461. https://doi.org/10.1001/jamanetworkopen.2023.12461

Marklund, M., Mattingly, T. J., Sahoo, S. K., Moran, A. E., Appel, L. J., & Matsushita, K. (2023). PS-BPP05-3: ESTIMATED IMPACT OF MEDICATION DISPENSING REFORMS FOR PUBLIC HYPERTENSION TREATMENT COVERAGE IN INDIA. Journal of Hypertension, 41(Suppl 1), e338–e339. https://doi.org/10.1097/01.hjh.0000916180.03738.26

Bryan, A., Mobley, C., Moran, A., Derington, C., Zhang, Y., Rodgers, A., Shea, S., & Bellows, B. (2022). EE310 Cost-Effectiveness of Initiating Antihypertensive Therapy with Single-Pill Combinations Versus Monotherapy in US Adults. Value in Health, 25(7), S394. https://doi.org/10.1016/j.jval.2022.04.555

Niyongere, J., Welty, T. E., Bell, M. W., Consalvo, D., Hammond, C., Leung, H., Patsalos, P. N., Ryan, M., Suansanae, T., Zhou, D., & Zuellig, H. (2022). Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force. Epilepsia Open, 7(2), 260–270. Portico. https://doi.org/10.1002/epi4.12583

Sahoo, S. K., Pathni, A. K., Krishna, A., Sharma, B., Cazabon, D., Moran, A. E., & Hering, D. (2022). ESTIMATES ON MEDICATION COST OF DRUG DOSE SPECIFIC TREATMENT PROTOCOL FOR HYPERTENSION MANAGEMENT IN PUBLIC AND PRIVATE HEALTHCARE SECTORS IN INDIA. Journal of Hypertension, 40(Suppl 1), e232. https://doi.org/10.1097/01.hjh.0000837844.63102.4a

Kohli-Lynch, C. N., Lewsey, J., Boyd, K. A., French, D. D., Jordan, N., Moran, A. E., Sattar, N., Preiss, D., & Briggs, A. H. (2022). Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. Circulation, 145(17), 1312–1323. https://doi.org/10.1161/circulationaha.121.057631